Effector mechanisms in demyelinating neuropathies

Revue Neurologique

Volumn 152, Issue 5, 1996, Pages 320-327

  Hartung, H P ^a,b   Zielasek, J ^a   Jung, S ^a   Toyka, K V ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LYMPHOTOXIN; TUMOR NECROSIS FACTOR ALPHA;

CONFERENCE PAPER; DEMYELINATION; GUILLAIN BARRE SYNDROME; HUMAN;

AUTOANTIBODIES; AUTOIMMUNE DISEASES; COMPLEMENT SYSTEM PROTEINS; CYTOKINES; DEMYELINATING DISEASES; HUMANS; MACROPHAGES;

EID: 0029683053     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (96)

1. ASPINALI, G.O., MCDONALD A.G., PANG H. (1994). Lipopolysaccharides of Campylobacter jejuni serotype O:19: structures of O antigen chains from the serostrain and two bacterial isolates from patients with the Guillain-Barre syndrome. Biochemistry, 31 : 250-255.
2. BRÜCK W., BRÜCK Y., DIEDERICH U., PIDDLESDEN S.J. (1995). The membrane attack complex of complement mediates peripheral nervous system demyelination in vitro. Acta Neuropathol, 90 : 601-607.
3. BUCHWALD B.M., WEISHAUPT A., TOYKA K.V., DUDEL J. (1995). Immunoglobulin G from a patient with Miller-Fisher Syndrome rapidly and reversibly depresses evoked quantal release at the neuromuscular junction of mice. Neuroscience Letters, 201 : 163-166.
4. BURTON D.R., WOOF J.M. (1992). Human antibody effector function. Adv Immunol, 51 : 1-84.
5. CAMMER W., BROSNAN C.F, BASILE C., BLOOM B.R., NORTON W.T. (1986). Complement potentiates the degradation of myelin proteins by plasmin: implications for a mechanism of inflammatory demyelination. Brain Res, 364 : 91-101.
6. CAMMER W., BROSNAN C.F., BLOOM B.R., NORTON W.T. (1981). Degradation of the P0, P1, and Pr proteins in peripheral nervous system myelin by plasmin: Implications regarding the role of macrophages in demyelinating diseases. J Neurochem, 36 : 1506-1514.
7. CHIA L.S., THOMPSON J.E., MOSCARELLO M.A. (1983). Disorder in human myelin induced by Superoxide radical: an in vitro investigation. Biochem Biophys Res Commun, 117 : 141-146.
8. CHIBA A., KISUNOKI S., SHIMIZU T., KANAZAWA I. (1992). Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol, 31 : 677-679.
9. ENDERS U., KARCH H., TOYKA K.V., MICHELS M., ZIELASEK J., PETTE M., HEESEMANN J., HARTUNG H.P. (1993). The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barre syndrome and in other neuroimmunological disorders. Ann Neurol, 34 : 136-144.
10. EXLEY A.R., SMITH N., WINER J.B. (1994). Tumour necrosis factor-alpha and other cytokines in Guillain-Barre syndrome. J Neurol, Neurosurg Psych 57 : 1118-1120.
11. FEASBY T.E., GILBERT J.J, HAHN A.F., NEILSON M. (1987). Complement depletion suppresses Lewis rat experimental allergic neuritis. Brain Res, 419 : 97-103.
12. GOLD R., ZIELASEK J., KIEFFER R., TOYKA K.V., HARTUNG H.-P. (1996). Secretion of nitrite by Schwann cells and its effect on T-cell activation in vitro. Cell Immunol. 168 : 69-77.
13. GRIFFIN J.W., GEORGE R., HO T. (1993). Macrophage systems in peripheral nerves. A review. J Exp Neurol. 52 : 553-560.
14. HALLIWELL B. (1992). Reactive oxygen species and the central nervous system. J Neurochem, 59 : 1609-1623.
15. HALLIWELL B., GUTTERIDGE J.M., CROSS C.E. (1992). Free radicals, antioxidants, and human disease: where are we now? J Lab Clin Med, 119 : 598-620.
16. HARTUNG H.-P., KIEFER R., GOLD R., TOYKA K.V (1996). Autoimmunity in the peripheral nervous system. In: Peripheral Neuropathies Part II. Edited by H-P Hartung. Bailliere's Clinical Neurology. Bailliere Tindall, London. Vol.5, 1-45.
17. HARTUNG H.-P., HADDING U. (1983). Synthesis of complement by macrophages and modulation of their functions through complement activation. Springer Seminars in Immunology, 6 : 283-326.
18. HARTUNG H.-P., X., POLLARD J.D., HARVEY G.K., TOYKA K.V. (1995a). Immunopathogenesis and treatment of the Guillain-Barré syndrome Part I. Muscle & Nerve, 18 : 137-153.
19. HARTUNG H.-P., POLLARD J.D., HARVEY G.K., TOYKA K.V (1995b). Immunopathogenesis and treatment of the Guillain-Barre syndrome Part II. Muscle & Nerve, 18 : 154-164.
20. HARTUNG H.P., SCHÄFER B., HEININGER K., STOLL G., TOYKA K.V. (1988a). The role of macrophages and eicosanoids in the pathogenesis of experimental allergic neuritis. Serial clinical, electrophysiological. biochemical and morphological observations. Brain, 111 : 1039-1059.
21. HARTUNG H.P., SCHÄFER B., HEININGER K., TOYKA K.V. (1988b). Suppression of experimental autoimmune neuritis by the oxygen radical scavengers Superoxide dismutase and catalase. Ann Neurol, 23 : 453-460.
22. HARTUNG H.P., SCHWENKE C., BITTER-SUERMANN D., TOYKA K.V. (1987). Guillain-Barre syndrome: activated complement components C3a and C5a in CSF. Neurology, 37 : 1006-1009.
23. HARTUNG H.-P., STOLL G., TOYKA K.V. (1993). Immune reactions in the peripheral nervous system. In: Peripheral Neuropathy. 3rd edn. Edited by PJ Dyck. PK Thomas, JW Griffin, PA Low. JF Poduslo. Philadelphia : Saunders. 418-444.
24. HARTUNG H.-P., TOYKA K.V. (1990). T-cell and macrophage activation in experimental autoimmune neuritis and Guillain-Barre syndrome. Ann Neurol, 27 Suppl : S57-S63.
25. HARVEY G.K., GOLD R., HARTUNG H.-P., TOYKA K.V. (1995). Nonneural-specific T lymphocytes can orchestrate inflammatory peripheral neuropathy. Brain, 118 : 1263-1272.
26. HARVEY G.K., TOYKA K.V. ZIELASEK J., KIEFFER R., SIMONIS C., HARTUNG H.P. (1995). Failure of anti-GM1 IgG or IgM to induce conduction block following intraneural transfer. Muscle & Nerve, 18 : 388-394.
27. HAYS A.P., LATOV N., TAKATSU M., SHERMAN W.H. (1987). Experimental demyelination of nerve induced by serum of patients with neuropathy and an anti-MAG IgM M-protein. Neurology, 37 : 242-256.
28. HEININGER K., SCHÄFER B., HARTUNG H.-P., FIERZ W., LININGTON C., TOYKA K.V. (1988). The role of macrophages in experimental autoimmune neuritis induced by a P2-specific T-cell line. Ann Neurol, 23 : 326-331.
29. HO T.W., MISHU B., LI C.Y., GAO C.Y., CORNBLATH D.R., GRIFFIN J.W., ASBURY A.K., BLASER M.J., MCKHANN G.M. (1995). Guillain-Barre syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain, 118 : 597-605.
30. ILYAS A.A., MITHEN F.A., CHEN Z.W., COOK S.D. (1991). Search for antibodies to neutral glycolipids in sera of patients with Guillain-Barre syndrome. J Neurol Sci. 102 : 67-75.
31. JACOBS B.C., ENDTZ H., VAN DER MECHÉ F.G.A., HAZENBERG M.P., ACHTEREEKTE H.A.M., VAN DOORN P.A. (1995). Serum anti-GQ1b IgG antibodies recognize surface epitopes on camplylobacter jejuni from patients with Miller Fisher syndrome. Ann Neurol, 37 : 260-264.
32. JUNG S., HUITINGA I., SCHMIDT B., ZIELASEK J., DIJKSTRA C.D., TOYKA K.V., HARTUNG H.P. (1993). Selective elimination of macrophages by dichlormethylene diphosphonate-containing liposomes suppresses experimental autoimmune neuritis. J Neurol Sci, 119 : 195-202.
33. JUNG S., TOYKA K.V., HARTUNG H.-P. (1995). Soluble complement receptor type 1 inhibits experimental autoimmune neuritis in Lewis rats. Neuroscience Letters, 200 : 167-170.
34. KHALILI-SHIEAZI A., ATKINSON P., GREGSON N., HUGHES R.A. (1993). Antibody responses to P0 and P2 myelin proteins in Guillain-Barre syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. J Neuroimmunol, 46 : 245-251.
35. KONAT G. W., WIGGINS R.C. (1985). Effect of reactive oxygen species on myelin membrane proteins. J Neurochem, 45 : 1113-1118.
36. KORNBERG A.J., PESTRONK A. (1995). Chronic motor neuropathies and lower motorneuron syndromes. In : Peripheral Neuropathies. Part I. Edited by H-P Hartung. Bailliere's Clinical Neurology, Bailliere Tindall, London, Vol. 4. 427-441.
37. KOSKI C.L. (1990). Characterization of complement-fixing antibodies to peripheral nerve myelin in Guillain-Barre syndrome. Ann Neurol, 27 Suppl : S44-S47.
38. KOSKI C.L., ESTEP A.E., SAWANT-MANE S., SHIN M.L., HIGHBARGER L., HÄNSCH G.M. (1996). Complement regulatory molecules on human myelin and glial cells : differential expression affects the deposition of activated complement proteins. J Neurochem, 66 : 303-312.
39. Koski C.L., Humphrey R., Shin M.L. (1985). Anti-peripheral myelin antibody in patients with demyelinating neuropathy: quantitative and kinetic determination of serum antibody by complement component 1 fixation. Proc Natl Acad Sci. USA, 82 : 905-909.
40. KOSKI C.L., SANDERS M.E., SWOVELAND P.T., LAWLEY T.J., SHIN M.L., FRANK M.M., JOINER K.A. (1987). Activation of terminal components of complement in patients with Guillain-Barre syndrome and other demyelinating neuropathies. J Clin Invest, 80 : 1492-1497.
41. KUSUNOKI S., CHIBA A., HITOSHI S., TAKIZAWA H., KANAZAWA I. (1995). Anti-Gal-C antibody in autoimmune neuropathies subsequent to mycoplasma infection. Muscle & Nerve, 18 : 409-413.
42. LATOV N., GROSS B.B., KASTELMAN J., FLANAGANT T., LAMME S., ALKAITIS D., OLARTE M.R., SHERMANN W.H., CHESS L., PENN A.S. (1981). Complement fixing antipenpheral nerve myelin antibodies in patients with inflammatory polyneuritis and with polyneuropathy and paraproteinemia. Neitrology, 31 : 1530-1534.
43. LININGTON C., BROSTOFF S.W. (1993). Peripheral nerve antigens. In : Peripheral Neuropathy. 3rd edn. Edited by PJ Dyck. PK Thomas, JW Griffin, PA Low, J Poduslo. Philadelphia : Saunders, 404-417.
44. MACKO C.E., SHEIKH K.A., LI C.Y., HO T.W., CORNBLATH D.R., MCKNANN G.M., ASBURY A.K., GRIFFIN J.W. (1996). Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol, in press.
45. MENDELL J.R., SAHENK Z., WHITAKER J.N., TRAPP B.D., YATES A.J., GRIGGS R.C., QUARLES R.H. (1985). Polyneuropathy and IgM monoclonal gammopathy: studies on the pathogenetic role of anti-myelin-associated glycoprotein antibody. Ann Neurol, 17 : 243-254.
46. MIESCHER G.C., STECK A.J. (1996). Paraproteinemic neuropathies. In : Peripheral Neuropathies. Part 11. Edited by H-P Hartung. Bailliere's Clinical Neurology, Bailliere Tindall, London. Vol. 5, 219-231.
47. MILETIC V.D., Frank M.M. (1995). Complement - immunoglobulin interactions. Current Opinion in Immunology, 7 : 41-47.
48. MONACO S., BONETTI B., FERRARI S., MORETTO G., NARDELLI E., TEDESCO F., MOLLNES T.E., NOBILE ORAZIO E., MANFREDINI E., BONAZZI L. et al. (1990). Complement-mediated demyelination in patients with IgM monoclonal gammopathy and polyneuropathy. N Engl J Med 322 : 649-652.
49. MONACO S., FERRARI S., BONETTI B., MORETTO G., KIRSHFINK M., NARDELLI E., NOBILE ORAZIO E., ZANUSSO G., RIZZUTO N., TEDESCO F. (1995). Experimental induction of myelin changes by anti-MAG antibodies and terminal complement complex. Journal of Neuropathology and Experimental Neurology, 54 : 96-104.
50. MOND J.J., VOS Q., LEES A., SNAPPER C.M. (1995). T cell independent antigen. Current Opininion in Immunology, 7 : 349-354.
51. NOBILE ORAZIO E., MANFREDINI E., CARPO M., MEUCCI N., MONACO S., FEERRARI S., BONETTI B., CAVALETTI G., GEMIGNANI F., DURELLI L. et al. (1994). Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol, 36 : 416-424.
52. OH S.J., CLAUSSEN G.C., ODABASI Z., PALMER C.P. (1995). Multifocal demyelinating motor neuropathy : Pathologic evidence of ' inflammatory demyelinating polyradiculoneuropathy'. Neurology, 45 : 1828-1832.
53. OOMES P.G., JACOBS B.C., HAZENBERG M.P.H., BÄNFER J.R.J., VAN DER MECHÉ F.G.A. (1995). Anti-GM1 IgG antibodies and campylobacter bacteria in Guillain-Barré syndrome : Evidence of molecular mimicry. Ann Neurol 38 : 170-175.
54. POLLARD J.D., WESTLAND K.W., HARVEY G.K., JUNG S., BONNER J., SPIES J.M., TOYKA K.V., HARTUNG H.-P. (1995). Activated T cells of nonneural specificity open the blood-nerve barrier to circulating antibody. Ann Neurology, 37 : 467-475.
55. PRINEAS J.W. (1994). Pathology of inflammatory demyelinating neuropathies. In : Inflammatory Neuropathies (McLeod, ed). Clinical Neurology, Bailliere Tindall, London. Vol. 3, 1-24.
56. REDFORD E.J., HALL S.M., SMITH K.J. (1995). Vascular changes and demyelination induced by the intraneural injection of tumour necrosis factor. Brain. 118 : 869-878.
57. REES J.H., GREGSON N.A., HUGHES R.A.C. (1995a) Anti-ganglioside GM1 antibodies in Guillain-Barré syndrome and their relationship to campylobacter jejuni infection. Ann Neurol, 38 : 809-816.
58. REES J.H., SOUDAIN S.E., GREGSON N.A., HUGHES R.A.C. (1995b). Cumpylobacter jujuni infection and Guillain-Barré syndrome. N Engl J Med, 313 : 1374-1379.
59. ROBERTS M., WILLISON H., VINCENT A., NEWSOM-DAVIS J. (1994). Serum factor in Miller-Fisher variant of Guillain-Barré syndrome and neurotransmitter release. Lancet, 343 : 454-455.
60. ROBERTS M., WILLISON H., VINCENT A., NEWSOM-DAVIS J. (1995). Multifocal motor neuropathy human sera block distal motor nerve conduction in mice. Ann Neurol, 38 : 111-118.
61. ROSTAMI A.M., BURNS J.B., ECCLESTON P.A., MANNING M.C., LISAK R.P., SILBERBERG D.H. (1987). Search for antibodies to galactocerebroside in the serum and cerebrospinal fluid in human demyelinating disorders. Ann Neurol 22 : 381-383.
62. SAID G., HONTEBEYRIE JOSKOWICZ M. (1992). Nerve lesions induced by macrophage activation. Res Immunol. 143 : 589-599.
63. SANTORO M., UNCINI A., CORBO M., STAUGAITIS S.M.,THOMAS F.P., HAYS A.P., LATOV N. (1992). Experimental conduction block induced by serum from a patient with anti-GM1 antibodies. Ann Neurol. 31 : 385-390.
64. SAWANT-MANE S., CLARK M.B., KOSKI C.L. (1991). In vitro demyelination by serum antibody from patients with Guillain-Barre syndrome requires terminal complement complexes. Ann Neurol, 29 : 397-404.
65. SCHABET M., WHITAKER J.N., SCHOTT K., STEVENS A., ZURN A., BÜHLER R., WIETHÖLTER H. (1991). The use of protease inhibitors in experimental allergic neuritis. J Neuroimmunol, 31 : 265-272.
66. SCHMIDT B., TOYKA K.V., KIEFER R., FULL J., HARTUNG H.-P., POLLARD J. (1995). Inflammatory infiltrates in sural nerve biopsies in Guillain-Barré syndrome and chronic inflammatory demyelinating neuropathy. Muscle & Nerve, 19 : 474-487.
67. SELMAJ K., RAINE C.S. (1988) Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol, 23 : 339-346.
68. SHARIEF M.K., MCLEAN B., THOMPSON E.J. (1993). Elevaled serum levels of tumor necrosis factor-alpha in Guillain-Barre syndrome [see comments]. Ann Neurol, 33 : 591-596.
69. SHIN N.L., CARNEY D.F. (1988). Cytotoxic action and other metabolic consequences of terminal complement proteins. Progress in Allergy, 40 : 44-81.
70. SOBUE G., YAMOTO S., HIRAYAMA M., MATSUOKA Y. UEMATSU H., SOBUE I. (1982). The role of macrophages in demyelination in experimental allergic neuritis. J Neurol Sci. 56 : 75-87.
71. SPIES J.M., POLLARD J.D., BONNER J.G., WESTLAND K.W., MCLEOD J.G. (1995). Synergy between antibody and P2-reactive T cells in experimental allergic neuritis. J Neuroimmunol, 57 : 77-84.
72. STEVENS A., LANG R., SCHABET M., WIETHÖLTER H., HAMMANN K. (1990). Spontaneous chemiluminescence activity of peripheral blood cells during experimental allergic neuritis (EAN). J Neuroimmunol, 27 : 33-40.
73. STOLL, G., JUNG S., JANDER S., VAN DER MEIDE P., HARTUNG H.-P. (1993). Tumor necrosis factor-alpha in immune-mediated demyelination and Wallerian degeneration of the rat peripheral nervous system. J Neuroimmunol, 45 : 175-182.
74. STOLI, G., SCHMIDT B., JANDER S., TOYKA K.V., HARTUNG H.P. (1991). Presence of the terminal complement complex (C5b-9) precedes myelin degradation in immune-mediated demyelination of the rat peripheral nervous system. Ann Neurol, 30 : 147-155.
75. TAKIGAWA T., YASUDA H., KIKKAWA R., SHIGETA Y., SAIDA T., KITASATO H. (1995). Antibodies against GM1 ganglioside affect K+ and Na+ currents in isolated rat myelinated nerve fibers. Ann Nenrol, 37 : 436-442.
76. TATUM A.H. (1993). Experimental paraproteinemic neuropathy, demyelination by passive transfer of human IgM anti-myclin-associated glycoprotein. Ann Neurol, 33 : 502-506.
77. TROJABORG W., GALASSI G., HAYS A.P., LOVELACE R.E., ALKAITIS M., LATOV N. (1989). Electrophysiologic study of experimental demyelination induced by serum of patients with IgM M proteins and neuropathy. Neurology, 39 : 1581-1586.
78. UNCINI A., SANTORO M., CORBO M., LUGARESI A., LATOV N.(1993). Conduction abnormalities induced by sera of patients with multifocal motor neuropathy and anti-GM1 antibodies. Muscle Nerve, 16 : 610-615.
79. VEDELER C.A., MATRE R. (1990). Peripheral nerve CR1 express in situ cofactor activity for degradation in C3b. J Neuroimmunol, 26 : 51-56.
80. VEDELER C.A., MATRE R. (1990). Peripheral nerve CR1 limit complement-mediated haemolysis. J Neuroimmunol, 30 : 95-98.
81. VEDELER C.A., MATRE R., FISCHER E. (1989). Isolation and characterization of complement receptors CRI from human peripheral nerves. J Neuroimmunol, 23 : 215-221.
82. VRIHSENDORP F.J., FLYNN R.E., PAPPOLLA M.A., KOSKI C.L. (1995). Complement depletion affects demyelination and inflammation in experimental allergic neuritis. J Neuroimmunol, 58 : 157-165.
83. VRIESENDORP F.J., MISHU B., BLASER M.J., KOSKI C.L. (1993). Serum antibodies to GM1, GD1b, peripheral nerve myelin, and Campylobacter jejuni in patients with Guillain-Barre syndrome and controls: correlation and prognosis [see comments]. Ann Neurol, 34 : 130-135.
84. WATSON S.L., WESTLAND K., POLLARD J.D. (1994). An electrophysiological and histological study of trypsin induced demyelination. J Neurol Sci. 126 : 116-125.
85. WILLISON H.J. (1994). Antiglycolipid antibodies in peripheral neuropathy: fact or fiction? J Neurol Neurosurg Psychiatry 57 : 1303-1307.
86. WILLISON H.J., TRAPP B.D., BACHER J.D., DALAKAS M.C., GRIFFIN J.W., QUARLES R.H. (1988). Demyelination induced by intrancural injection of human antimyelin-associated glycoprotein antibodies. Muscle Nerve, 11 : 1169-1176.
87. WILLISON H.J., VEITCH J. (1994). Immunoglobulin subclass distribution and binding characteristics of anti-GQ1b antibodies in Miller Fisher syndrome. J Neuroimmunol, 50 : 159-165.
88. WILLISON H.J., VEITCH J., PATERSON G., KENNEDY P.G. (1993). Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside. J Neurol Neurosurg Psychiatry, 56 : 204-206.
89. YUKI N., ICHIHASHI Y., TAKI T. (1995). Subclass of IgG antibody to GMI epitope-bearing lipopoplysaccharide of Campylobacter jejuni in patients with Guillain-Barré syndrome. J Neuroimmunol, 60 : 161-164.
90. YUKI N., SATO S., TSUJI S., OHSAWA T., MIYATAKE T. (1993a), Frequent presence of anti-GQ1b antibody in Fisher's syndrome. Nenrology, 43 : 414-417.
91. YUKI N., TAKI T., INAGAKI F., KASAMA T., TAKAHASHI M., SAITO K., HANDA S., MIYATAKE T. (1993b). A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J Exp Med, 178 : 1771-1775.
92. YUKI N., TAKI T., TAKAHASHI M., SAITO K., YOSHINO H., TAI T., HANDA S., MIYATAKE T. (1994). Molecular mimicry between GQ1b ganglioside and lipopolysaccharides of campylobacter jejuni isloaled from patients with Fisher's syndrome. Ann Neurol, 36 : 791-793.
93. YUKI N., YAMADA M., SATO S., OHAMA E., KAWASE Y., IKUTA F., MIYATAKE T. (1993). Association of IgG anti-GD1a antibody with severe Guillain-Barre syndrome Muscle & Nerve, 16 : 642-647.
94. YUKI N., YOSHINO H., SATO S., MIYATAKE T. (1990). Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology, 40 : 1900-1902.
95. ZIELASEK J., JUNG S., GOLD R., LIEW F.Y., TOYKA K.V., HARTUNG H.-P. (1995). Administration of nitric oxide synthuse inhibitors in experimental autoimmune neuritis and experimental autoimmune encephalomyelitis. J Neuroimmunol, 58 : 81-88.
96. ZIELASEK J., RITTER G., MAGI S., HARTUNG H.-P., TOYKA K.V. and Participating Laboratories (1994). A comparative trial of anti-glycoconjugate antibody assays : IgM antibodies to GM1. J Neurol, 241 : 475-480.